# A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

> **NCT02395042** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 59 (actual)

## Conditions studied

- Cystitis, Interstitial
- Ulcer

## Interventions

- **DRUG:** LiRIS®
- **DRUG:** LiRIS Placebo

## Key facts

- **NCT ID:** NCT02395042
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2017-06-29
- **Final completion:** 2017-11-20
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02395042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02395042, "A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02395042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*